Halozyme Therapeutics Inc 's Revenue in the fiscal year 2025 $ 1,396.61 millions
Halozyme Therapeutics Inc 's Revenue in the fiscal year 2024 $ 1,015.32 millions
Halozyme Therapeutics Inc 's Revenue in the fiscal year 2023 $ 829.25 millions
Halozyme Therapeutics Inc 's Revenue in the fiscal year 2022 $ 660.12 millions
Halozyme Therapeutics Inc 's Revenue in the fiscal year 2021 $ 443.31 millions
HALO Revenue second quarter 2026 Y/Y Growth Comment
Halozyme Therapeutics Inc reported Revenue rise of 47.67% year on year in the second quarter 2026, to $ 481.00 millions, this is lower than Halozyme Therapeutics Inc 's recent average Revenue rise of 75.04%.
Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue growth. While Halozyme Therapeutics Inc ' s Revenue jump of 47.67% ranks overall at the positon no. 481 in the second quarter 2026.
HALO Revenue ( Y/Y Growth %)
2026
2025
2024
2023
4th Quarter
December
-
51.6 %
29.55 %
26.74 %
3rd Quarter
September
-
22.12 %
34.28 %
3.37 %
2nd Quarter
June
47.67 %
40.79 %
4.66 %
45.07 %
1st Quarter
March
42.23 %
35.22 %
20.81 %
38.25 %
FY
-
37.55 %
22.44 %
-
Financial Statements
Halozyme Therapeutics Inc 's second quarter 2026 Revenue
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Halozyme Therapeutics Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
308.55 %
24.52 %
-89.49 %
(Dec 31 2012)
HALO's II. Quarter Q/Q Revenue Comment
Halozyme Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 27.68%, to $ 481.00 millions, from $376.71 millions in the first quarter. HALO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Halozyme Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 390.
Halozyme Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 27.68%, to $ 481.00 millions, from $376.71 millions in the first quarter. HALO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Halozyme Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 390.
Halozyme Therapeutics Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 1,663.74
$ 1,508.46
$ 1,396.61
$ 1,242.85
$ 1,178.67
Y / Y Revenue Growth (TTM)
41.15 %
39.12 %
37.55 %
31.19 %
34.97 %
Year on Year Revenue Growth Overall
Ranking
# 476
# 609
# 274
# 579
# 594
Seqeuential Revenue Change (TTM)
10.29 %
8.01 %
12.37 %
5.45 %
8.7 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1660
# 1752
# 913
# 565
# 1964
Cumulative Revenue growth Comment
Halozyme Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 41.15% year on year, to $ 1,664 millions if the fiscal year would have ended in Jun 30 2026. Halozyme Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 35.45% and higher than 39.12% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 10.29 % from $1508.46 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at35.45%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 10.29 % increase from $1508.46 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 115 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 476, from total ranking in previous quarter at 609.
Halozyme Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 41.15% year on year, to $ 1,664 millions if the fiscal year would have ended in Jun 30 2026. Halozyme Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 35.45% and higher than 39.12% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 10.29 % from $1508.46 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at35.45%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 10.29 % increase from $1508.46 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 115 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 476, from total ranking in previous quarter at 609.
About Halozyme Therapeutics Inc Revenue Growth Rates (HALO), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
82.08%